Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer

NCT01215162 | Completed Phase 2 DMC

• 2 other identifiers: 1681-02MCS066
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

The study is being done to determine the tolerance to single fraction intra-operative electron irradiation (IOERT) and external beam photon irradiation (EBRT) following lumpectomy for T1/T2N0M0 breast cancer. IOERT is used in lieu of the 5-8 days of electron beam boost irradiation that is usually given after EBRT. Data from two centers as well as preliminary data from a randomized trial in Europe suggest that IOERT boost is well tolerated and efficacious. In our study, patients will undergo standard lumpectomy and sentinel lymph node sampling or axillary dissection. After the lumpectomy, IOERT of 10 Gy will be delivered in a single fraction to the tumor bed by a mobile electron machine in the operating room. EBRT to the whole breast will be administered once the surgical wound has healed adequately. The primary objective is to determine the feasibility and acute patient tolerance to IOERT and EBRT after lumpectomy. Secondary objectives include assessment of local control and distant control of disease, as well as evaluation of long-term side effects and cosmetic outcome of the treatment.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (3)

• Determine the feasibility and acute patient tolerance of IOERT and EBRT after lumpectomy for patients with stage T1/T2N0M0 breast cancer.

  To determine the acute skin reaction, breast edema, pnemonitis, cardiac side effects during radiation using RTOG acute toxicity scale

  weekly evaluation during 5 weeks of radiation

• Determine the local tumor control and distant tumor control rates for patients with stage T1/T2N0M0 breast cancer.

  every 6 months follow-up for 5 years, then yearly to end in 04/2013

• Determine long-term side effects and cosmetic outcome of IOERT to tumor bed and EBRT after lumpectomy for patients with stage T1/T2N0Mo breast cancer.

  To determine the late skin reaction, breast edema, pneumonitis, cardiac side effects during radiation using RTOG late toxicity scale

  every 6 months follow-up for 5 years, then yearly to end in 04/2013

Study Arms (1)

Single arm study

EXPERIMENTAL

Patients with stage T1/T2No breast cancer receiving breast conserving treatment

Radiation: Intra-operative radiation to tumor bed

Interventions

Intra-operative radiation to tumor bed RADIATION

IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.

Single arm study

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

Eligibility: 1. Histologically proven primary invasive breast carcinoma. 2. Tumor pathologically determined \<= 5cm in diameter. 3. Single, discrete, well-defined primary tumor. 4. Any micro-calcifications must be focal. A specimen radiograph is required after lumpectomy to assure removal of all malignant appearing calcifications. 5. Pathologically negative surgical margins. 6. Axillary lymph node status can be determined by level I and II lymph node dissection or sentinel lymph node sampling. 7. ECOG performance status 0-2. Contraindications: 1. Multicentric disease and/or diffuse malignant appearing microcalcifications. 2. Evidence of metastatic breast cancer. 3. Axillary lymph node involvement. 4. Pre-existing collagen vascular disease except rheumatoid arthritis that does not require immunosuppressive therapy. 5. Prior irradiation to the ara of planned radiation field. 6. Pregnant or lactating women.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Scottsdale, Arizona, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: August 7, 2009
• First Posted: October 6, 2010
• Study Start: January 1, 2003
• Primary Completion: January 1, 2005
• Study Completion: January 1, 2013
• Last Updated: April 3, 2014

Record last verified: 2014-04

Locations

US (1)